Results 31 to 40 of about 24,744 (229)

Safety outcomes of antidiabetic medications: A comprehensive review of the EU summaries of product characteristics and international clinical practice guidelines

British Journal of Clinical Pharmacology, EarlyView.
Aims Information on the safety profile of antidiabetic medications is essential for informed treatment decisions in type 2 diabetes mellitus. Although this information is available in regulatory documents of individual drugs, a comprehensive overview across all approved antidiabetics is lacking.
David Liang, Daniala L. Weir, Safana Thevasahayam, Vera H. M. Deneer, Arno Siebes, Helga Gardarsdottir   +5 more
wiley   +1 more source

How do new therapeutic strategies for PCOS management influence the health of the affected individuals? The narrative review

Journal of Education, Health and Sport, 2022
Introduction and purpose: Management of polycystic ovary syndrome (PCOS) is difficult since the exact pathogenic mechanism has not been established yet.
Aleksandra Wójcik, Jan Wojtas, Mikołaj Margas, Konrad Warchoł, Karol Stępniak   +4 more
doaj   +1 more source

Disentangling Sex Differences in Sulfonylurea Drug Response With Genome‐Wide Association Studies in Individuals With Type 2 Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
A sex‐stratified genome‐wide association study of sulfonylurea response identified sex‐specific genetic loci associated with HbA1c reduction in individuals with type 2 diabetes. Replication and functional validation supported a male‐specific association at the TMEM64/NECAB1 locus, highlighting the potential of sex‐informed pharmacogenomics to advance ...
Joseph H. Breeyear, John S. House, Mark Kvale, Stella Nam, Farida S. Akhtari, Hetal S. Shah, Monique M. Hedderson, Kathleen M. Giacomini, Josyf C. Mychaleckyj, Alessandro Doria, Michael J. Wagner, Josephine H. Li, Sook Wah Yee, John B. Buse, Richard P. Woychik, Daniel M. Rotroff, Alison A. Motsinger‐Reif   +16 more
wiley   +1 more source

Crosstalk between PPARγ Ligands and Inflammatory-Related Pathways in Natural T-Regulatory Cells from Type 1 Diabetes Mouse Model

Biomolecules, 2018
Immunomodulation, as a means of immunotherapy, has been studied in major research and clinical laboratories for many years. T-Regulatory (Treg) cell therapy is one of the modulators used in immunotherapy approaches. Similarly, nuclear receptor peroxisome
S. Zulkafli Nor Effa, Nik Soriani Yaacob, Norazmi Mohd Nor   +2 more
doaj   +1 more source

Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis

Frontiers in Pharmacology, 2023
Background and aims: Hypoglycemic agents are the primary therapeutic approach for the treatment of diabetes and have been postulated to impact pancreatic cancer (PC) incidence in diabetic patients.
Zimo Zhao, Xinyi He, Yan Sun
doaj   +1 more source

Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid‐Related Adverse Events Following Surgery for Breast Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Pain is a key determinant of quality‐of‐life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid‐related adverse effects remain unclear.
Jyun‐Heng Lai, Anton L V Avanceña, Juan P Cata, Jamie C. Barner, Sharon H. Giordano, Chanhyun Park, Hui Zhao, Kirk E. Evoy, John K. Lin, Jennifer C. Spencer, Mariana Chavez‐MacGregor, Kelly K. Hunt, Kerollos Nashat Wanis   +12 more
wiley   +1 more source

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas

Clinical and Translational Science
The risk of psoriasis in diabetic patients has rarely been explored. This study aims to compare the risk of incident psoriasis in patients with Type 2 diabetes (T2D) who initiate dipeptidyl peptidase‐4 inhibitors (DPP‐4is) or thiazolidinediones (TZDs ...
Wei‐Sheng Chen, Tzu‐Min Lin, Yu‐Sheng Chang, Yu‐Chuan Shen, Hui‐Ching Hsu, Tzu‐Tung Kuo, Shu‐Chuan Chen, Jin‐Hua Chen, Chi‐Ching Chang   +8 more
doaj   +1 more source

Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism

Journal of Lipid Research, 2004
Peroxisome proliferator-activated receptor γ (PPARγ) activation or overexpression induces caveolin-1 (cav-1) expression in several cell types. The objective of this study was to investigate if PPAR agonists could also regulate the cav-1 gene in ...
Gemma Llaverias, Manuel Vázquez-Carrera, Rosa M. Sánchez, Véronique Noé, Carlos J. Ciudad, Juan C. Laguna, Marta Alegret   +6 more
doaj   +1 more source

Chemotherapy and Chemoprevention by Thiazolidinediones [PDF]

BioMed Research International, 2015
Thiazolidinediones (TZDs) are synthetic ligands of Peroxisome-Proliferator-Activated Receptor gamma (PPARγ). Troglitazone, rosiglitazone, and pioglitazone have been approved for treatment of diabetes mellitus type II. All three compounds, together with the first TZD ciglitazone, also showed an antitumor effect in preclinical studies and a beneficial ...
Eleonore Fröhlich, Richard Wahl
openaire   +2 more sources

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

iNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little, Stefan Offermanns, Haaglim Cho, Zhiping Liu, Pinglian Yang, Qiaozhu Su, Henry Wade, Wah Yang, Danielle Kamato, Neale Cohen, Alex Bobik, Iqra Ilyas, Suowen Xu   +12 more
wiley   +1 more source